Advertisement

Search Results

Advertisement



Your search for Alice Goodman matches 1109 pages

Showing 1 - 50


Expert Point of View: Michael Jain, MD, PhD

Michael Jain, MD, PhD, of the Moffitt Cancer Center, Tampa, Florida, commented on both studies with the combination of brentuximab vedotin/nivolumab. “For older patients, ABVD [doxorubicin, bleomycin, vinblastine, dacarbazine] is not easy to tolerate, and it would be good to find an easier...

immunotherapy
lymphoma

Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma

The combination of brentuximab vedotin and nivolumab is making headway as first-line therapy for older adults with Hodgkin lymphoma and as salvage therapy for adults with relapsed or refractory classic Hodgkin lymphoma, according to separate studies presented at the 2019 Annual Meeting &...

breast cancer

Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer

A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with...

leukemia
immunotherapy

Expert Point of View: Howard J. Weinstein, MD

Commenting on the blinatumomab study, Howard J. Weinstein, MD, Chief of Pediatric Hematology-Oncology at Massachusetts General Hospital for Children and Harvard Medical School in Boston, said: “These are very promising results for children, adolescents, and young adults who have had a first...

immunotherapy
leukemia

Blinatumomab Outperforms Chemotherapy as Post-Reinduction Consolidation Therapy in Younger Patients With B-Cell ALL

Blinatumomab was superior to standard chemotherapy in children, adolescents, and young adults at the first relapse of B-cell acute lymphoblastic leukemia (ALL) as post-reinduction consolidation therapy prior to hematopoietic stem cell transplant (HSCT), according to the results of a late-breaking...

Expert Point of View: Gary Schiller, MD

At the press conference where these data were presented, moderator Gary Schiller, MD, of the University of California, Los Angeles, explained that although chimeric antigen receptor (CAR) T-cell therapy is a major advance in cellular immunotherapy, enabling killing of cancer cells in blood and bone ...

hematologic malignancies
immunotherapy

Preliminary Data on Multiantigen-Targeted CAR NK-Cell Therapy for B-Cell Malignancies

A novel off-the-shelf chimeric antigen receptor natural killer cell (CAR-NK) product called FT596 may prove to be an active therapy for B-cell malignancies. This agent is designed to overcome several challenges inherent in CAR T-cell therapy, including CD19-antigen escape, which leads to relapse in ...

breast cancer

Expert Point of View: Steven J. Isakoff, MD, PhD

Steven J. Isakoff, MD, PhD, a medical oncologist at Massachusetts General Hospital, Boston, commented on the results of the DESTINY-Breast01 trial. “These data are extraordinarily encouraging, suggesting we will have another new option for patients with metastatic HER2-positive breast cancer. The...

breast cancer

Novel Antibody-Drug Conjugate Shows Efficacy in Women With Pretreated, Metastatic HER2-Positive Breast Cancer

The novel antibody-drug conjugate [fam-] trastuzu­mab deruxtecan (T-DXd) achieved high response rates and durable responses in heavily pretreated patients with HER2-positive metastatic breast cancer, according to results of the phase II DESTINY-Breast 01 trial presented at the 2019 San Antonio...

breast cancer

Expert Point of View: Sherene Loi, MD

Sherene Loi, MD, of Peter MacCallum Cancer Centre, Melbourne, Australia, said that the BROCADE3 trial was positive because it met its primary endpoint. However, she expressed some reservations about adopting this combination as a new standard for HER2-negative BRCA-mutated advanced breast cancer....

breast cancer

Veliparib/Chemotherapy Combination Active in HER2-Negative BRCA-Positive Advanced Breast Cancer

The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to carboplatin/paclitaxel chemotherapy significantly improved progression-free survival in patients with advanced HER2-negative breast cancer and germline BRCA mutation compared with placebo plus chemotherapy, according to...

solid tumors

Making Inroads With Interventional Oncology in the Treatment of Solid Tumors

  At the recent 2019 Symposium on Clinical Interventional Oncology (CIO) in Miami, course directors Constantino Peña, MD, FSIR, and Ripal Gandhi, MD, FSIR, FSVM, had a lot to say about this burgeoning field of oncology. In particular, interventional oncology is making inroads in therapeutic...

immunotherapy
lymphoma

ASH 2019: Early Data Signal Potential for Bispecific Antibody in Non-Hodgkin Lymphoma

The investigational bispecific antibody mosunetuzumab is showing activity in preliminary studies of patients with non-Hodgkin lymphoma (NHL), including those who are refractory to or relapsed after third-line chimeric antigen receptor (CAR) T-cell therapy. If preliminary findings are validated by...

prostate cancer

Is Nonmetastatic Castration-Resistant Prostate Cancer a Valid Disease Category?

Does nonmetastatic castration-resistant prostate cancer really exist? Although it is considered a disease category, it turns out that the definition depends on the type of imaging used. Many patients with castration-resistant prostate cancer who were categorized as “nonmetastatic” on conventional...

prostate cancer

Biomarker-Driven Treatment Selection for Prostate and Other Genitourinary Cancers

As the Nobel Laureate Bob Dylan wrote, “The times they are a-changin’.” Heather Cheng, MD, PhD, Associate Professor, University of Washington, Associate Member, Fred Hutchinson Cancer Research Center, and Director, Seattle Cancer Care Alliance, Prostate Cancer Genetics Clinic, quoted this line in...

kidney cancer
immunotherapy

Immunotherapy Strategies in Renal Cell Carcinoma: Present and Future

Immunotherapy with checkpoint inhibitors is now considered a standard of care for the front-line treatment of advanced renal cell carcinoma. Despite better outcomes with these agents, there is still room for improvement. At the 2019 Chemotherapy Foundation Symposium, Robert J. Motzer, MD, of...

breast cancer

Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer

In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but there is no preferred option for third-line treatment and beyond. At the 2019 Chemotherapy Foundation Symposium, Shanu Modi, MD,...

Expert Point of View: Marleen Kok, MD

“This is currently the largest data set with information on retreatment,” said formal study discussant Marleen Kok, MD, of the Netherlands Cancer Institute, Amsterdam, The Netherlands. She noted there was a partial response in 11% and stable disease in 60%. “Upon initial treatment, partial...

immunotherapy
solid tumors

Study Finds Durvalumab Retreatment Active in Some Patients With Advanced Solid Tumors

Immunotherapy with checkpoint inhibitors offers a proportion of patients a chance at long-term disease control, resembling cure in some patients. Among the many questions about immunotherapy that remain to be resolved is whether patients who discontinue therapy and develop progressive disease can...

Expert Point of View: Sanjay Popat, FRCP, PhD

Formal discussant of the CheckMate 227 trial, Sanjay Popat, FRCP, PhD, of the Royal Marsden Hospital, London, had some reservations about endorsing nivolumab/ipilimumab as a new standard of care, mainly related to toxicity. “The landscape of treating advanced non–small cell lung cancer has changed ...

lung cancer
immunotherapy

Nivolumab/Ipilimumab: Another First-Line Option for Advanced NSCLC

The combination of nivolumab and ipilimumab improved overall survival compared with chemotherapy as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) expression of at least 1%, according to the results of CheckMate 227....

prostate cancer

Expert Point of View: Silke Gillessen, MD

Formal discussant Silke Gillessen, MD, of the Division of Cancer Sciences, University of Manchester, United Kingdom, agreed that this study is practice-changing. “The study was well designed and addressed an unmet clinical need that is commonly seen in the clinic. Until now we had no randomized...

prostate cancer

Third-Line Cabazitaxel Improves Outcomes in Patients With Metastatic Prostate Cancer

Third-line treatment with cabazitaxel extended progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer in the CARD trial. These results provide the first evidence from a randomized phase III trial for a survival benefit with third-line therapy, and ...

Expert Point of View: Thomas Powles, MD, PhD

In metastatic urothelial carcinoma, the bar has been set low, with a median survival of 1 year in cisplatin-eligible patients and 6 to 8 months when platinum-based therapy fails to elicit a response in patients, explained formal study discussant Thomas Powles, MD, PhD, Director, Bart’s Cancer...

bladder cancer

IMvigor130 Trial: Atezolizumab Plus Chemotherapy for Metastatic Urothelial Cancer

Treatment with atezolizumab plus chemotherapy extended progression-free survival by 1.9 months vs chemotherapy alone in patients with metastatic urothelial cancer, according to the early results of the IMvigor130 trial, which were presented at the European Society for Medical Oncology (ESMO)...

Expert Point of View: Eleni Efstathiou, MD

Formal study discussant Eleni Efstathiou, MD, of MD Anderson Cancer Center, Houston, was enthusiastic about the PROfound trial results. “This is the first phase III targeted therapy trial to deliver positive outcomes in metastatic castration-resistant prostate cancer,” she stated. “This is truly a ...

prostate cancer

Targeted Therapy Moves Into Metastatic Castration-Resistant Prostate Cancer With Strong Showing by Olaparib and Rucaparib

Treatment with olaparib delayed disease progression, and early survival data suggest a positive trend in favor of olaparib compared with newer hormonal agents in men with pretreated metastatic castration-resistant prostate cancer and homologous recombinant repair genetic alterations—specifically...

Expert Point of View: Sherene Loi, MD, PhD

Formal discussant Sherene Loi, MD, PhD, Professor of Cancer Therapeutics at the Peter MacCallum Cancer Centre, Melbourne, Australia, characterized the results of KEYNOTE-522 as “exciting.” “This is the first phase III neoadjuvant study in triple-negative breast cancer. Despite breast cancer not...

breast cancer
immunotherapy

Phase III Evidence Supports Neoadjuvant Immunotherapy Plus Chemotherapy for Early Triple-Negative Breast Cancer

Immunotherapy has changed the treatment paradigms for melanoma, lung cancer, bladder cancer, and renal cancer. Now, checkpoint inhibitor therapy is making inroads in triple-negative breast cancer—one of the most difficult-to-treat aggressive types of breast cancer. The addition of the checkpoint...

Expert Point of View: Pilar Garrido, MD, PhD

At a press conference at the European Society for Medical Oncology (ESMO) Congress 2019, Pilar Garrido, MD, PhD, of Ramon y Cajal University Hospital, Madrid, commented on the FLAURA trial: “These results are good news for patients with lung cancer, which is the most common cause of cancer deaths. ...

lung cancer

FLAURA Trial: First-Line Osimertinib Improves Overall Survival in EGFR-Mutated Advanced Lung Cancer

First-line treatment with osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to late-breaking final overall survival results of the phase III FLAURA...

Expert Point of View: Lizza E. Hendriks, MD, PhD

Formal discussant of the ASCEND-7 trial, Lizza E. Hendriks, MD, PhD, of the Maastricht University Medical Center, The Netherlands, said that up to 50% of patients with non–small cell lung cancer (NSCLC) will develop central nervous system (CNS) metastases, and these patients can have poor quality...

lung cancer

Ceritinib Active in Treating Brain Metastases in Non–Small Cell Lung Cancer

The ALK inhibitor ceritinib demonstrated efficacy in patients with ALK-positive non–small cell lung cancer (NSCLC) and active brain metastases, according to the results of the ASCEND-7 trial reported at the European Society for Medical Oncology (ESMO) Congress 2019.1 Substantial intracranial...

prostate cancer

Expert Point of View: Gert de Meerleer, MD

Commenting on both RADICALS-RT and the meta-analysis, formal discussant Gert de Meerleer, MD, of the University Hospital, Leuven, Belgium, stated: “A big applause for these trials. I agree with both conclusions and congratulate both groups of authors for finding noncommercial funding.” Dr. de...

prostate cancer

Studies Suggest Early Salvage Radiotherapy May Be Preferable to Adjuvant Radiotherapy After Prostatectomy

Early salvage radiotherapy appears to be a better choice after radical prostatectomy for men with prostate cancer than adjuvant radiotherapy, according to late-breaking results from the ­RADICALS-RT trial and the ARTISTIC meta-analysis of three trials that included RADICALS-RT. Observation after...

taxotere
opdivo
keytruda

Studies Report Prolonged Long-Term Survival With Immunotherapy vs Chemotherapy in Advanced NSCLC

Longer-term follow-up of patients with advanced non–small cell lung cancer (NSCLC) who are treated with immunotherapy have appreciably extended survival at 5 years, suggesting that for some patients, this disease can be managed as a chronic condition. These findings are based on two presentations ...

Expert Point of View: Robert Doebele, MD, PhD, and Roy S. Herbst, MD, PhD

Discussant of the LIBRETTO-001 trial, Robert Doebele, MD, PhD, of the University of Colorado Anschutz Medical Campus in Aurora, Colorado, was enthusiastic about the response rates reported in this preliminary trial. “Older trials of multikinase inhibitors have shown response rates in the range of ...

lung cancer

Selpercatinib: Precision Medicine for RET Fusion–Positive NSCLC

Selpercatinib (LOXO-292), a RET kinase inhibitor, demonstrated antitumor activity in the lungs and brain and durable responses with acceptable tolerability in patients with RET fusion–positive non–small cell lung cancer (NSCLC), according to an updated analysis of the LIBRETTO-001 registration...

lung cancer
immunotherapy

Expert Point of View: Myung-Ju Ahn, MD, and Roy Herbst, MD, PhD

Formal discussant Myung-Ju Ahn, MD, of Samsung Medical Center Sungkyunkwan University, Seoul, South Korea, said that the CASPIAN results were similar to those of IMpower133, which found that the addition of the immune checkpoint inhibitor atezolizumab to etoposide/carboplatin significantly...

tecentriq
paraplatin
imfinzi
etopophos
toposar

Durvalumab Plus Chemotherapy: New Option for Extensive-Stage SCLC

The addition of the immune checkpoint inhibitor durvalumab to standard therapy significantly improved overall survival vs standard therapy alone for patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to a preplanned interim analysis of the phase III CASPIAN...

zytiga
erleada
jevtana
nubeqa
taxotere
xtandi
keytruda
xofigo
provenge

Greater Consensus From Global Experts on Controversies in Prostate Cancer

In late August, experts from around the globe convened in Basel, Switzerland, at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) to discuss controversial areas related to the management of advanced prostate cancer. Although the full proceedings of the conference will be published in...

Expert Point of View: Alex A. Adjei, MD, PhD

Alex A. Adjei, MD, PhD, of the Mayo Clinic, Rochester, Minnesota, also commented on this phase I study of AMG 510. “Although it is a little bit early to tell and the number of patients with non–small cell lung cancer treated is still small, AMG 510 is the first potential true breakthrough in the...

lung cancer

Novel KRAS Inhibitor Shows Activity in Early Study of Advanced Non–Small Cell Lung Cancer

The investigational KRAS inhibitor AMG 510 yielded clinical activity in patients with advanced non–small cell lung cancer (NSCLC), according to updated results of a small ongoing phase I trial reported at the 2019 International Association for the Study of Lung Cancer (IASLC) World Conference on...

lung cancer

Studies Report Prolonged Long-Term Survival With Immunotherapy vs Chemotherapy in Advanced NSCLC

Longer-term follow-up of patients with advanced non–small cell lung cancer (NSCLC) who are treated with immunotherapy have appreciably extended survival at 5 years, suggesting that for some patients, this disease can be managed as a chronic condition. These findings are based on two presentations ...

lung cancer
immunotherapy

Expert Point of View: Alex A. Adjei, MD, PhD

Alex A. Adjei, MD, PhD, of Mayo Clinic, Rochester, Minnesota, who was not involved in KEYNOTE-189 or KEYNOTE-021, provided some perspective on the exploratory analyses of tumor mutational burden from these and other studies. “Four studies at this meeting presented data on tumor mutational burden...

yervoy
keytruda
opdivo
alimta

Tumor Mutational Burden Disappoints as Biomarker for Treatment Response in Exploratory Analyses of Nonsquamous NSCLC

Tumor mutational burden failed to prove effective as a biomarker for response to chemotherapy plus checkpoint inhibitor or chemotherapy alone as first-line treatment for nonsquamous non–small cell lung cancer (NSCLC) in two different exploratory analyses of KEYNOTE trials.1,2 In both analyses,...

kidney cancer
prostate cancer
immunotherapy

Novel Treatments Under Study in Renal Cell Carcinoma and Prostate Cancer

There were numerous notable presentations at the 2019 Genitourinary Cancers Symposium, many of which were covered in The ASCO Post over the past few months. To add to our continued coverage of this meeting, here are some highlights from studies focusing on novel therapeutics in renal cell carcinoma ...

kidney cancer
prostate cancer
immunotherapy

Novel Treatments Under Study in Renal Cell Carcinoma and Prostate Cancer

There were numerous notable presentations at the 2019 Genitourinary Cancers Symposium, many of which were covered in The ASCO Post over the past few months. To add to our continued coverage of this meeting, here are some highlights from studies focusing on novel therapeutics in renal cell carcinoma ...

breast cancer
kidney cancer
sarcoma
lymphoma
multiple myeloma

Notable Presentations at ASCO 2019 Included Studies in Sarcoma, Lymphoma, Myeloma, and Breast and Kidney Cancers

The 2019 ASCO Annual Meeting featured a wealth of presentations on important topics. In addition to our regular news coverage of the meeting, we present below some highlights of other studies that add to our knowledge base for treatment of various cancers. Olaratumab in Soft-Tissue Sarcoma...

prostate cancer

Study Highlights on Novel Agents and Supportive Care Strategies in Prostate Cancer

In addition to our regular coverage of major news stories from the 2019 ASCO Annual Meeting, here is an additional roundup of important studies related to prostate cancer. ARAMIS: Darolutamide and Quality of Life Darolutamide, a next-generation androgen receptor antagonist, significantly prolonged...

Advertisement

Advertisement



Advertisement